IVERIC bio, Inc. (ISEE) News

IVERIC bio, Inc. (ISEE): $13.16

-0.44 (-3.24%)

POWR Rating

Component Grades













Add ISEE to Watchlist
Sign Up

Industry: Biotech


of 402

in industry

Filter ISEE News Items

ISEE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ISEE News Highlights

  • For ISEE, its 30 day story count is now at 8.
  • Over the past 22 days, ISEE's stories per day has been in a clear uptrend, growing by about 0.23 per 4 days.
  • BIO are the most mentioned tickers in articles about ISEE.

Latest ISEE News From Around the Web

Below are the latest news stories about IVERIC bio Inc that investors may wish to consider to help them evaluate ISEE as an investment opportunity.

IVERIC bio, Inc. (ISEE) Q4 2021 Earnings Call Transcript

Representing IVERIC bio today are Mr. Glenn Sblendorio, chief executive officer; Dr. Pravin Dugel, president; Mr. And we are pleased to welcome Mr. Tony Gibney as chief business and strategy officer.

Yahoo | February 24, 2022

Iveric Bio Reports Fourth Quarter and Full Year 2021 Operational Highlights and Financial Results

PARSIPPANY, N.J., February 24, 2022--Iveric Bio announced financial and operating results for the fourth quarter and full year ended Dec. 31, 2021 and provided a general business update.

Yahoo | February 24, 2022

Iveric Bio to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022

NEW YORK, February 17, 2022--Iveric Bio announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, February 24, 2022.

Yahoo | February 17, 2022

Top 10 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

In this article, we discuss the top 10 stock picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. You can skip our detailed analysis of Akkaraju and Dybbs’ history, investment philosophy, and hedge fund performance, and go directly to the Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital. Dr. Srinivas Akkaraju […]

Yahoo | February 17, 2022

Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® in Patients with Geographic Atrophy

NEW YORK, February 11, 2022--Iveric Bio announced a post-hoc analysis from the GATHER1 Zimura Phase 3 clinical trial, which evaluated various GA growth parameters.

Yahoo | February 11, 2022

Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022

NEW YORK, February 07, 2022--Iveric announced that new post-hoc analyses from the GATHER1 Zimura® Phase 3 trial will be presented at Angiogenesis, Exudation, and Degeneration 2022

Yahoo | February 7, 2022

Were Hedge Funds Right About IVERIC bio, Inc. (ISEE)?

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

Yahoo | February 5, 2022

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, February 02, 2022--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to one newly-hired, non-executive employee.

Yahoo | February 2, 2022

Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors

NEW YORK, January 06, 2022--Iveric Bio announced today the election of Christine Ann Miller to its Board of Directors, effective immediately.

Yahoo | January 6, 2022

Iveric Bio to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, January 04, 2022--Iveric Bio will participate in the H.C. Wainwright BioConnect Virtual Conference, being held virtually from January 10-13, 2022.

Yahoo | January 4, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5168 seconds.